Stock OPGN OPGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

OpGen, Inc. Share Price

Equities

OPGN

US68373L4068

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
0.5149 USD -3.21% Intraday chart for OpGen, Inc. -18.27% +22.60%
04-24 OpGen Gets Notice of Noncompliance From Nasdaq MT
03-26 Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading MT

Financials

Sales 2021 4.31M 345M Sales 2022 2.61M 209M Capitalization 7.57M 606M
Net income 2021 -34M -2.72B Net income 2022 -37M -2.96B EV / Sales 2021 6.51 x
Net cash position 2021 10.9M 873M Net Debt 2022 7.38M 591M EV / Sales 2022 5.74 x
P/E ratio 2021
-0.87 x
P/E ratio 2022
-0.18 x
Employees 93
Yield 2021 *
-
Yield 2022
-
Free-Float 90.52%
More Fundamentals * Assessed data

Chart OpGen, Inc.

Dynamic Chart

Latest news about OpGen, Inc.

OpGen Gets Notice of Noncompliance From Nasdaq MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading MT
OpGen, Inc. Announces Management Changes CI
OpGen, Inc. Announces Chief Executive Officer Changes CI
OpGen, Inc. announced that it expects to receive $3 million in funding CI
Earnings Flash (OPGN) OPGEN Posts Q3 Revenue $699,022 MT
OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
OpGen to Raise $1 Million From Private Placement Amid Talks For 'Potential Strategic' Deal MT
OpGen, Inc. announced that it expects to receive $1 million in funding CI
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected MT
Investors Await Inflation Data, Consumer Sentiment Report as US Futures Trend Higher Friday MT
Top Premarket Gainers MT
North American Morning Briefing : China Angst -2- DJ
HC Wainwright Downgrades OpGen to Neutral From Buy MT
Opgen Exploring Options CI
More news

Latest transcript on OpGen, Inc.

Logo OpGen, Inc.
OpGen, Inc., Q2 2023 Earnings Call, Aug 10, 2023
More transcripts

Analyst Recommendations on OpGen, Inc.

HC Wainwright Downgrades OpGen to Neutral From Buy MT
Alliance Global Downgrades OpGen to Neutral From Buy, Adjusts Price Target to $0.67 From $1.25 MT
Alliance Global Adjusts OpGen's Price Target to $1.25 From $3, Reiterates Buy Rating MT
OPGEN : Alliance Global Partners Adjusts Price Target on OpGen to $7 From $5.65, Maintains Buy Rating MT
OPGEN : Alliance Global Partners Adjusts OpGen PT to $5.65 From $5, Maintains Buy Rating MT
More recommendations

Press releases OpGen, Inc.

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K AQ
OpGen : Management Change/Compensation - Form 8-K PU
OpGen Announces Acquisition of Preferred Stock by David Lazar AQ
OpGen : Accelaration/Increase of Financial Obligation - Form 8-K PU
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update AQ
More press releases

Quotes and Performance

1 day-3.21%
1 week-18.27%
Current month-25.91%
1 month-31.35%
3 months+47.96%
6 months-22.22%
Current year+22.60%
More quotes

Highs and lows

1 week
0.48
Extreme 0.48
0.63
1 month
0.48
Extreme 0.48
0.84
Current year
0.24
Extreme 0.24
0.99
1 year
0.17
Extreme 0.165
3.84
3 years
0.17
Extreme 0.165
74.40
5 years
0.17
Extreme 0.165
304.00
10 years
0.17
Extreme 0.165
54 400.00
More quotes

Managers and Directors - OpGen, Inc.

Managers TitleAgeSince
Albert Weber DFI
 Director of Finance/CFO 60 31/12/21
Johannes Bacher COO
 Chief Operating Officer 55 31/03/20
Oliver Schacht PRN
 Corporate Officer/Principal 53 31/03/20
Members of the board TitleAgeSince
Oliver Schacht PRN
 Corporate Officer/Principal 53 31/03/20
More insiders

Quotes

Date Price Change Volume
26/04/24 0.5149 -3.21% 437,254
25/04/24 0.532 -5.51% 196,829
24/04/24 0.563 -8.16% 175,679
23/04/24 0.613 +2.51% 58,363
22/04/24 0.598 -5.08% 95,108

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes

Company Profile

OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Company’s subsidiaries include Curetis GmbH and Ares Genetics GmbH.
Sector
Biotechnology & Medical Research
Calendar
08/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
OPGEN, INC. Stock OpGen, Inc.
+22.60% 6.5M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. OPGN Stock